Pierre Fabre Group
↗Castres, France
Pierre Fabre is a French multinational pharmaceutical and dermocosmetics company headquartered in Castres, France, founded in 1962 by pharmacist Pierre Fabre. With over 60 years of expertise, the company operates in 43 countries across 6 continents with approximately 10,000 employees and generates revenues of approximately €3.1 billion (2024). The company is structured as an alliance of pharmaceutical and dermocosmetics expertise, with a unique ownership model where the Pierre Fabre Foundation (a government-recognized public-interest foundation) serves as the majority shareholder, reflecting its commitment to improving access to quality medicines and healthcare, particularly in Africa and Southeast Asia. Pierre Fabre's medical division focuses on oncology, dermatology, rare diseases, primary care, and family health, while its dermocosmetics division encompasses major international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, and Elgydium. The company manufactures nearly 90% of its products in France and distributes products in 120 countries worldwide.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, Dermatology, Rare Diseases, Dermocosmetics
SIZE & FINANCIALS
Employees:10000+
Revenue:$3.1B-$3.5B
Founded:1962
Ownership:private
Status:operating
FUNDING
Investors:Pierre Fabre Foundation (majority shareholder)
PIPELINE
Stage:Preclinical|Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 2-3 (PFL-002/VERT-002, STX-241, PFL-721, PFL-241)
Modalities:Small molecule inhibitors, Monoclonal antibodies, Immunoconjugates, Allogeneic T-cell therapies, Gene therapy, Vinca alkaloids
Trial Phases:-
FDA Approvals:3
EMA Approvals:6
CORPORATE STRUCTURE
Subsidiaries:Pierre Fabre Pharmaceuticals (US), Pierre Fabre Dermo-Cosmetics, MÊME Cosmetics (acquired), 43 subsidiaries globally
Key Partnerships:Scorpion Therapeutics: Co-development of STX-721 and STX-241 for NSCLC, Atara Biotherapeutics: EBVALLO (tabelecleucel) commercialization rights, transferred from Atara, Array Biopharmaceuticals (Pfizer): BRAFTOVI/MEKTOVI development and commercialization, Antares Therapeutics: Acquired Vertical Bio and VERT-002 program
COMPETITION
Position:Niche Player
Competitors:Roche, Novartis, Merck, Bristol Myers Squibb, Pfizer, Beiersdorf, L'Oreal, GSK +3 more
LEADERSHIP
Key Executives:
Eric Ducournau - Chief Executive Officer (CEO) of Pierre Fabre Group
Marie-Andrée Gamache - Chief Executive Officer (CEO) of Medical Care Business Unit
Vincent Huraux - CEO, Operations Business Unit
Jean-Luc Lowinski - CEO, Medical Care Business Unit (former)
Audrey Ricard Campion - Head of Research and Development, Dermo-Cosmetics & Personal Care
Scientific Founders:Pierre Fabre
Board Members:Roch Doliveux (Supervisory Board Member), Marie-Anne Aymerich (Supervisory Board Member), Jean-Laurent Bonnafe (Supervisory Board Member), Isabelle Girolami (Supervisory Board Member), Hervé Hoppenot (Supervisory Board Member), Rachel Marouani (Supervisory Board Member), Florence Parly (Supervisory Board Member), Pierre-Yves Revol (Supervisory Board Member), Olivier Sadran (Supervisory Board Member), Eduardo Sanchiz (Supervisory Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pierre Fabre Group. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.